Hailong Hu

University of North Carolina at Chapel Hill — United States

Medicine · Health Sciences

23h-index2.0kcitations151works3.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bladder and Urothelial Cancer Treatments(56), Urinary and Genital Oncology Studies(29), Ferroptosis and cancer prognosis(17), Cancer Immunotherapy and Biomarkers(16), Epigenetics and DNA Methylation(14)

Publications151 total

E2F transcription factors as multimodal biomarkers for pan-cancer management
Scientific Reports·2025Open Access
Analysis of the diagnostic value of peripheral blood immune inflammatory indicators of female bladder pain syndrome
Frontiers in Surgery·2025Open Access
Quantitative and large-scale investigation of human TCR-HLA cross-reactivity
Science Advances·2025· 1 citedOpen Access
Significance of neutrophil extracellular traps and low-density granulocytes in advanced chronic kidney disease (stage 5D) cases with COVID-19
Renal Failure·2025· 1 citedOpen Access
2684O ARTEMIS-002: A phase II study of HS-20093 in patients with relapsed or refractory sarcomas
Annals of Oncology·2025
Choledochal cyst with “absence” of the distal common bile duct: A case report
Asian Journal of Surgery·2025Open Access
Amyand's hernia: a case report and literature review
Frontiers in Pediatrics·2025Open Access
IL-15RαFc superagonist SHR-1501 with or without bacille Calmette Guerin (BCG) for high-risk non-muscle invasive bladder cancer (NMIBC): A phase 1/2 study.
Journal of Clinical Oncology·2025
Impact of pelvic lymph node dissection on survival outcomes in non-muscle invasive bladder cancer: A multicenter retrospective study.
Journal of Clinical Oncology·2025
Prognostic impact of histological subtypes in non-muscle-invasive UTUC: Propensity matched analysis.
Journal of Clinical Oncology·2025
Updated results of a phase II study of RC48 in combination with tislelizumab as pre-transurethral resection neoadjuvant therapy for extensive high-risk non–muscle-invasive bladder cancer with HER2 overexpression.
Journal of Clinical Oncology·2025· 1 cited
Neoadjuvant tislelizumab combined with disitamab vedotin (RC48) for patients with Her-2 expressing upper tract urothelial carcinoma: A pilot study.
Journal of Clinical Oncology·2025
Giant spindle cell tumor of the abdomen: A case report
Asian Journal of Surgery·2025Open Access
PD12-03 SHOULD (VERY) HIGH-RISK NMIBC PATIENTS UNDERGOING RC OPT FOR PELVIC LYMPH NODE DISSECTION: PRELIMINARY RESULTS OF A PROSPECTIVE MUTICENTER COHORT STUDY
The Journal of Urology·2025
Development and validation of a nomogram for predicting prostatic urethral involvement in bladder cancer
Scientific Reports·2025· 2 citedOpen Access
Kidney multiome-based genetic scorecard reveals convergent coding and regulatory variants
Science·2025· 29 citedOpen Access
Utilizing vaginal natural orifice to facilitate bowel manipulation during totally intracorporeal ileal conduit construction: a retrospective cohort study
Annals of Medicine·2025· 2 citedOpen Access
Development and validation of a glycolysis-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer
Frontiers in Immunology·2025· 5 citedOpen Access
The critical role of endoplasmic reticulum stress and the stimulator of interferon genes (STING) pathway in kidney fibrosis
Kidney International·2024· 23 citedOpen Access
Human genetics identify convergent signals in mitochondrial LACTB-mediated lipid metabolism in cardiovascular-kidney-metabolic syndrome
Cell Metabolism·2024· 13 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Yuri Oh(18), Qian Guo(14), Qiong Wu(13), Katalin Suszták(12), Daqian Yang(11), Ning Gu(11), Xingpei Fan(10), Xiangjuan Wei(10), Boya Zhang(9), Hongbo Liu(9), Yujie Feng(9), Hongjuan He(8), Ning Gu(7), Amin Abedini(6), Poonam Dhillon(5), Ziyuan Ma(5), Chuanpeng Liu(5), Tomohito Doke(4), Dhanunjay Mukhi(4), Xin Sheng(4)